Rashmin Adesara, MD
Family Medicine · Indianapolis, INNPI 1699975185
Payments from drug & device makers
Across 152 payments — averaging $33.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Smith+Nephew$2K
- Novo Nordisk$418
- Integra Lifesciences Corporation$409
- AstraZeneca$378
- GSK$358
- Bayer$311
- plus $2K from 25 others
What the payments were for
- Consulting fees$1,50030%
- Speaking & faculty fees$1242%
- Food & beverage$3,42968%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Smith+Nephew | 4 | $1,620 |
| Novo Nordisk | 19 | $418 |
| Integra Lifesciences Corporation | 8 | $409 |
| AstraZeneca | 10 | $378 |
| GSK | 22 | $358 |
| Bayer | 14 | $311 |
| Pfizer | 12 | $202 |
| Lilly USA, LLC | 15 | $186 |
| Bioventus LLC | 2 | $171 |
| Amgen | 4 | $142 |
| Organogenesis Inc. | 1 | $124 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $111 |
| Abbott | 4 | $78 |
| Novartis | 3 | $74 |
| AbbVie(2 entities) | 4 | $68 |
| Astellas Pharma US Inc | 3 | $61 |
| Exact Sciences | 3 | $44 |
| Hologic Sales And Service, LLC | 2 | $35 |
| Eisai Inc. | 2 | $35 |
| Johnson & Johnson | 3 | $34 |
| Collegium Pharmaceutical, Inc. | 1 | $24 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Dexcom, Inc. | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $21 |
| Seqirus USA Inc | 1 | $20 |
| RGH Enterprises LLC | 1 | $16 |
| Cranial Technologies, Inc | 1 | $16 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $14 |
| E.r. Squibb & Sons, L.L.C. | 1 | $14 |
| Misonix Inc | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COLLAGENASE SANTYL$1,500
- OMNIGRAFT$260
- PRIMATRIX$260
- MEDIHONEY$260
- TCC-EZ$260
- AMNIOEXCEL$260
- FARXIGA$125
- BREZTRI$125
- Apligraf$124
- Dermagraft$124
- Puraply/Affinity/NuTech$124
- SHINGRIX$116
- Ozempic$105
How this compares
$5,053 in reported general payments places this provider in the 85th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 96 | $134,446 |
| JardianceEmpagliflozin | 82 | $84,806 |
| MounjaroTirzepatide | 66 | $83,426 |
| TrulicityDulaglutide | 45 | $76,696 |
| EliquisApixaban | 28 | $46,052 |
| RybelsusSemaglutide | 29 | $43,091 |
| LinzessLinaclotide | 17 | $18,532 |
| JanuviaSitagliptin Phosphate | 18 | $17,594 |
| Breo ElliptaFluticasone/Vilanterol | 22 | $12,330 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 56 | $12,260 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 13 | $12,078 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $11,964 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $10,252 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 14 | $9,471 |
| Humalog Kwikpen U-200Insulin Lispro | 17 | $7,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $418 | $177,537125 claims |
| Lilly USA, LLCMounjaro, Trulicity | $186 | $160,121111 claims |
| PfizerEliquis | $202 | $46,05228 claims |
| GSKBreo Ellipta, Shingrix, Trelegy Ellipta | $358 | $34,06292 claims |
| AbbVieLinzess | $68 | $18,53217 claims |
| Smith+NephewSantyl | $1,620 | $6,44413 claims |
| AstraZenecaSymbicort | $378 | $2,64912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Indianapolis
- Blair BrengleIndianapolis$10.6M
- Steven SmithIndianapolis$2.5M
- Richard TannerIndianapolis$1.6M
- Richard FeldmanIndianapolis$476K
- Joe BanksIndianapolis$294K
- Jakoda SniderIndianapolis$107K
- Robert ClutterIndianapolis$77K
- Gaylen KeltonIndianapolis$42K
- Daniela LoboIndianapolis$38K
- Haihong MaoIndianapolis$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.